Figure 7 | Scientific Reports

Figure 7

From: Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway

Figure 7The alternative text for this image may have been generated using AI.

E-cadherin, vimentin, MAPK14 and p-mTOR expression in IH-treated HGC-27 cells. (A) The E-cadherin mRNA expression in IH-treated HGC-27 cells detected by qRT-PCR. (B) The vimentin mRNA expression in IH-treated HGC-27 cells detected by qRT-PCR. (C)The MAPK14 transcription in IH-treated HGC-27 cells detected by qRT-PCR. (D) The E-cadherin, vimentin, MAPK14 and p-mTOR protein expression in IH-treated HGC-27 cells detected by western blot. (E) E-cadherin bands densitometry quantified using Image J. (F) viementin bands densitometry quantified by Image J. (G) MAPK14 band densitometry quantified using Image J. (H) p-mTOR band densitometry quantified using Image J. Values are mean ± SD, n = 3, *P < 0.05, **P < 0.01 vs. control.

Back to article page